ArticleBMC cancer2025
α-hederin inhibits cervical cancer progression by inducing DNA damage-dependent cell cycle blockade and apoptosis.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mitochondrial reprogramming in cervical cancer: crosstalk with tumor immunity, HPV oncogenic signaling, and therapeutic resistance.Frontiers in immunology · 2026Review
- Cervical human papillomavirus: the therapeutic target of botanical drugs.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundCervical cancer incidence has not decreased significantly despite widespread use of HPV vaccines and screening measures. PURPOSE: This study explored the potential of α-Hederin in the treatment of cervical cancer.
methodsCCK8, EdU staining assay, flow cytometry were conducted for apoptosis, cell cycle, ROS, and mitochondrial membrane potential. Mechanism effects of α-hederin on cervical cancer cells were investigated using transcriptome sequencing, bioinformatics analysis, and single-cell sequencing. Further in-depth detection of key proteins with western blot, immunofluorescence, overexpression of CHK1 gene, DNA damage inhibitors, and NAC inhibitors were performed to study the regulation of the cell cycle. In vivo nude mice tumorigenicity experiments and metabolomics analysis of the tumor tissue were also performed.
resultsα-Hederin significantly inhibited SiHa and HeLa cell growth, promoted apoptosis, and inhibited migration and invasion of cervical cancer cells. Sequencing and bioinformatics analysis revealed that α-hederin mainly regulated cell cycle, DNA replication, P53, and other signaling pathways to inhibit the proliferation of cervical cancer cells and inhibited the G2M phase of the cell cycle, mainly by suppressing CDK1 and CyclinB expression. α-hederin may use ATM-CHK1-CDC25B/CDC25C and ATM-P53-P21 to regulate CDK1/Cycline B activity. Inhibition of this action significantly promoted G2M phase block. In vivo experiment indicated that the drug can effectively inhibit cervical cancer growth.
conclusionα-hederin may be an effective drug to inhibit cervical cancer and has a good development prospect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.